{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:04:55Z","timestamp":1784181895161,"version":"3.55.0"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is an emerging public health concern in India, with rising incidence and varying survival outcomes. This study aimed to evaluate 5\u2010year overall survival and identify prognostic factors among prostate cancer patients treated at Tata Memorial Hospital (TMH), Mumbai.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included all patients newly diagnosed with prostate cancer between January and December 2017 who received cancer\u2010directed treatment at TMH. Patients were followed through 2022. Clinico\u2010epidemiological variables including age, PSA levels, Gleason grade, clinical extent (EAU risk group classification), intent, completion status and treatment modality were analysed. Kaplan\u2013Meier survival curves and Cox proportional hazards models were used to assess survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 421 patients were included, with a mean (SD) age of 66\u2009\u00b1\u2009(8.39) years and a median (IQR) PSA of 45.9 (17\u2013154) ng\/ml. All patients were symptomatic at presentation, predominantly with urinary complaints (90.5%), followed by bone pain (3.6%) or both (5.9%). At diagnosis, 15.2% had localized disease, 25.8% had locally advanced disease, and 58.4% had metastatic cancer. The overall 5\u2010year survival rate was 61%. Prognostic factors significantly associated with survival included age, PSA, Gleason grade and disease extent. Patients with PSA\u2009&gt;\u20091000\u2009ng\/ml had the poorest prognosis (33% 5\u2010year survival). Survival varied by age group, declining from 66% in those aged 66\u201375\u2009years to 45% in patients &gt;75\u2009years, although this trend was not statistically significant in adjusted analysis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.46). Disease extent demonstrated a strong survival gradient: 89% in localized disease, 79% in locally advanced and 41% in metastatic cancer, with metastatic disease showing a significantly increased adjusted mortality risk (HR: 4.59;\n                      <jats:italic>p<\/jats:italic>\n                      0.004). Curative treatment intent was associated with markedly better outcomes, with a 5\u2010year survival of 81% compared to 40% among those receiving palliative care. Similarly, treatment adherence had a substantial impact on prognosis, with patients completing therapy achieving a 65% 5\u2010year survival rate, in contrast to only 12% among those with incomplete treatment (adjusted HR: 3.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Treatment modality also influenced survival: patients treated with ADT alone had the lowest 5\u2010year survival (35%) and a significantly higher mortality risk (adjusted HR:1.65;\n                      <jats:italic>p<\/jats:italic>\n                      0.01), whereas outcomes were more favourable with radical prostatectomy with adjuvant therapy (75%; adjusted HR: 1.21\n                      <jats:italic>p<\/jats:italic>\n                      0.80).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Survival in prostate cancer is strongly influenced by clinical extent at diagnosis, PSA, Gleason grade and treatment. Improving early detection, expanding multimodal treatment strategies and ensuring treatment completion are critical to enhancing outcomes in India.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bco2.70155","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:35:51Z","timestamp":1770359751000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre"],"prefix":"10.1002","volume":"7","author":[{"given":"Aswathy","family":"P","sequence":"first","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-8751","authenticated-orcid":false,"given":"Sivaranjini","family":"Kannusamy","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Oak","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-4337","authenticated-orcid":false,"given":"Gagan","family":"Prakash","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Department of Surgical Oncology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Joshi","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Department of Medical Oncology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Department of Radiation Oncology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Menon","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Department of Pathology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Cheulkar","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lokhande","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Balasubramaniam","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Dikshit","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"},{"name":"Division of Cancer Care, Hospital Cancer Registries &amp; Survival Studies Centre for Cancer Epidemiology  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute  Mumbai India"},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)  Mumbai India"},{"name":"Centre for Cancer Epidemiology  Mumbai India"},{"name":"Tata Memorial Centre  Mumbai India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.174774"},{"key":"e_1_2_9_3_1","unstructured":"Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed March 27 2024 fromhttps:\/\/gco.iarc.fr\/"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00122"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mgene.2014.07.007"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810084"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.52908"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/UCCI.UCCI_6_24"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.IJU_478_20"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2011.03.010"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102386"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.ijc_1145_21"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_409_22"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_38_23"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.4.2595"},{"key":"e_1_2_9_17_1","unstructured":"Cancer of the Prostate \u2010 Cancer Stat Facts.SEER. Accessed March 25 2024 fromhttps:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"e_1_2_9_18_1","unstructured":"International Classification of Diseases (ICD). Accessed December 8 2023 fromhttps:\/\/www.who.int\/standards\/classifications\/classification-of-diseases"},{"key":"e_1_2_9_19_1","unstructured":"EAU guidelines on prostate cancer \u2010 EPIDEMIOLOGY AND AETIOLOGY \u2010 Uroweb. Uroweb \u2010 European Association of Urology. Accessed August 14 2024 fromhttps:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/epidemiology-and-aetiology"},{"key":"e_1_2_9_20_1","unstructured":"Statistical software for data science | Stata. Accessed June 30 2025 fromhttps:\/\/www.stata.com\/"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2607"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.58144"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12389"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015764507609"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.4192"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.025"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2075"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209454"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.09.008"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.01.001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04116-8"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_2_9_33_1","unstructured":"International variation in prostate cancer incidence and mortality rates \u2010 PubMed. Accessed September 18 2025 fromhttps:\/\/pubmed.ncbi.nlm.nih.gov\/22424666\/"},{"issue":"3","key":"e_1_2_9_34_1","first-page":"4056","article-title":"Evaluation of prostate cancer characteristics in four populations worldwide","volume":"15","author":"Zeigler\u2010Johnson CM","year":"2008","journal-title":"Can J Urol"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_61_19"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2022\/57485.17161"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.IJU_37_20"},{"key":"e_1_2_9_38_1","unstructured":"Routine screening with serum PSA not needed says ICMR.The Times of India.https:\/\/timesofindia.indiatimes.com\/india\/routine-screening-with-serum-psa-not-needed-says-icmr\/articleshow\/104939920.cms?utm_. November 3 2023. Accessed September 18 2025."}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bco2.70155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:12:23Z","timestamp":1784178743000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.70155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/bco2.70155"],"URL":"https:\/\/doi.org\/10.1002\/bco2.70155","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70155"}}